Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients.
Ueda T, Fujita K, Nishimoto M, Shiraishi T, Miyashita M, Kayukawa N, Nakamura Y, Sako S, Ogura R, Fujihara A, Minami T, Hongo F, Okihara K, Yoshimura K, Uemura H, Ukimura O.
Ueda T, et al. Among authors: okihara k.
World J Urol. 2022 Dec;40(12):2939-2946. doi: 10.1007/s00345-022-04200-2. Epub 2022 Nov 4.
World J Urol. 2022.
PMID: 36331614